Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01655745 · ClinicalTrials.gov registry record · NA

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT01655745 is a NA study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01655745, a NA study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

This prospective pilot study will enroll 30 patients with cT2/T3-N0-M0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned. This pilot study is designed to provide preliminary information on the accuracy of \[18F\] Fluorodeoxyglucose Positron Emission Tomography MRI (FDG-PET-MRI) in the staging of muscle-invasive bladder cancer.

Interventions

  • PROCEDURE FDG PET/MR

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2012-07-24
Est. Completion 2019-02-01
Phase NA

What the Registry Record Tells You About NCT01655745

The ClinicalTrials.gov registry entry for NCT01655745 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which FDG PET/MR is the first listed.

NCT01655745 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01655745 about?

NCT01655745 is a clinical study titled "Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer". This prospective pilot study will enroll 30 patients with cT2/T3-N0-M0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned. This pilot study is designed to provide preliminary information on the accuracy of \[18F\] Fluorodeoxyglucose Positron ...

What is the current status of trial NCT01655745?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2012-07-24. Estimated completion is 2019-02-01.

What interventions are being tested in trial NCT01655745?

The interventions under investigation include: FDG PET/MR (PROCEDURE).

Who is sponsoring clinical trial NCT01655745?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.